MET is required for the recruitment of anti-tumoural neutrophils

Nature

Volumn 522, Issue 7556, 2015, Pages 349-353

  Finisguerra, Veronica ^a,b   Di Conza, Giusy ^a,b   Di Matteo, Mario ^a,b   Serneels, Jens ^a,b   Costa, Sandra ^a,b,c,d   Thompson, A A Roger ^e   Wauters, Els ^a,f,g   Walmsley, Sarah ^e,i   Prenen, Hans ^f   Granot, Zvi ^h   Casazza, Andrea ^a,b   Mazzone, Massimiliano ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF MINHO   (Portugal)

^d UNIVERSITY OF MINHO   (Portugal)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g University of Leuven   (Belgium)

^h HEBREW UNIVERSITY OF JERUSALEM   (Israel)

ⁱ UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPMATINIB; INDUCIBLE NITRIC OXIDE SYNTHASE; JNJ 38877605; NITRIC OXIDE; PF 04217903; PHOSPHOTRANSFERASE INHIBITOR; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; SCATTER FACTOR RECEPTOR;

BLOOD; CANCER; DRUG; GROWTH; HOMINID; LIGAND; MUTATION; NITRIC OXIDE; PATHOGENICITY; PHENOTYPE; PROTEIN; RODENT; SURVIVAL; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER THERAPY; CELL KILLING; CELL MIGRATION; COLITIS; CONTROLLED STUDY; ENDOTHELIUM; FEMALE; GENE DELETION; HUMAN; HUMAN CELL; INFLAMMATION; MET ONCOGENE; METASTASIS; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERITONITIS; PHENOTYPE; PRIORITY JOURNAL; PROTO ONCOGENE; RASH; TUMOR GROWTH; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; DEFICIENCY; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; NEOPLASMS; NEUTROPHIL; PATHOLOGY; SECRETION (PROCESS); SOLUBILITY; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENE DELETION; HEPATOCYTE GROWTH FACTOR; HUMANS; INFLAMMATION; MALE; MICE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; NEUTROPHILS; NITRIC OXIDE; PROTO-ONCOGENE PROTEINS C-MET; SOLUBILITY; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84934973340     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14407     Document Type: Article

References (35)

1. Gherardi, E., Birchmeier, W., Birchmeier, C. & Vande Woude, G. Targeting MET in cancer: rationale and progress. Nature Rev. Cancer 12, 89-103 (2012).
2. Bertotti, A. et al. Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci. Signal. 2, ra80 (2009).
3. Lennerz, J. K. et al.METamplification identifies asmall and aggressive subgroup of esophagogastric adenocarcinomawith evidence of responsiveness to crizotinib. J. Clin. Oncol. 29, 4803-4810 (2011).
4. Choueiri, T.K. et al.Phase II andbiomarker study of the dualMET/VEGFR2inhibitor foretinib in patientswith papillary renal cell carcinoma. J. Clin. Oncol. 31, 181-186 (2013).
5. Comoglio, P.M., Giordano, S. & Trusolino, L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nature Rev. Drug Discov. 7, 504-516 (2008).
6. Bussolino, F. et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cellmotility and growth. J. Cell Biol. 119, 629-641 (1992).
7. Liu, Y. et al. Hepatocyte growth factor and c-Met expression in pericytes: implications for atherosclerotic plaquedevelopment. J. Pathol.212,12-19(2007).
8. Chen, Q., DeFrances, M. C. & Zarnegar, R. Induction of met proto-oncogene (hepatocyte growth factor receptor) expression during human monocytemacrophage differentiation. Cell Growth Differ. 7, 821-832 (1996).
9. Baek, J. H., Birchmeier, C., Zenke, M. & Hieronymus, T. The HGF receptor/Met tyrosine kinase is a key regulator of dendritic cell migration in skin immunity. J. Immunol. 189, 1699-1707 (2012).
10. Adams, D. H. et al. Hepatocyte growth factor and macrophage inflammatory protein 1b: structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T cells. Proc. Natl Acad. Sci. USA 91, 7144-7148 (1994).
11. Tesio, M. et al. Enhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signaling. Blood 117, 419-428 (2011).
12. Takeda, Y. et al.Macrophage skewing byPhd2haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature 479, 122-126 (2011).
13. Elliott, E. R. et al. Deletion of Syk in neutrophils prevents immune complex arthritis. J. Immunol. 187, 4319-4330 (2011).
14. Kishi, Y. et al. SystemicNK4 gene therapy inhibits tumor growth andmetastasis of melanoma and lung carcinoma in syngeneic mouse tumor models. Cancer Sci. 100, 1351-1358 (2009).
15. Pennacchietti, S. et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347-361 (2003).
16. Moghul, A. et al. Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: evidence for rapid decay of the 8kb c-MET transcript. Oncogene 9, 2045-2052 (1994).
17. Dai, J. Y., DeFrances, M. C., Zou, C., Johnson, C. J. & Zarnegar, R. The Met protooncogene is a transcriptional target of NFkB: implications for cell survival. J. Cell. Biochem. 107, 1222-1236 (2009).
18. Suga, H. et al. IFATS collection: fibroblast growth factor-2-induced hepatocyte growth factor secretion by adipose-derived stromal cells inhibits postinjury fibrogenesis through a c-Jun N-terminal kinase-dependent mechanism. Stem Cells 27, 238-249 (2009).
19. Fridlender, Z. G. & Albelda, S. M. Tumor-associated neutrophils: friend or foe? Carcinogenesis 33, 949-955 (2012).
20. Garber, K. MET inhibitors start on road to recovery. Nature Rev. Drug Discov. 13, 563-565 (2014).
21. Wright, H. L., Moots, R. J., Bucknall, R. C. & Edwards, S. W. Neutrophil function in inflammation and inflammatory diseases. Rheumatology 49, 1618-1631 (2010).
22. Passegué, E., Wagner, E. F. & Weissman, I. L. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 119, 431-443 (2004).
23. Van Ziffle, J. A. & Lowell, C. A. Neutrophil-specific deletion of Syk kinase results in reduced host defense to bacterial infection. Blood 114, 4871-4882 (2009).
24. Abram, C. L., Roberge, G. L., Pao, L. I., Neel, B. G. & Lowell, C. A. Distinct roles for neutrophils and dendritic cells in inflammation and autoimmunity in motheaten mice. Immunity 38, 489-501 (2013).
25. Albanesi, M. et al. Neutrophils mediate antibody-induced antitumor effects in mice. Blood 122, 3160-3164 (2013).
26. Lagasse, E. & Clerc, R. G. Cloning and expression of two human genes encoding calcium-binding proteins that are regulated during myeloid differentiation. Mol. Cell. Biol. 8, 2402-2410 (1988).
27. Hamm, A. et al.PHD2regulates arteriogenicmacrophages through TIE2signalling. EMBO Mol. Med. 5, 843-857 (2013).
28. Neufert, C., Becker, C. & Neurath, M. F. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nature Protocols 2, 1998-2004 (2007).
29. Moolenbeek, C. & Ruitenberg, E. J. The "Swiss roll": a simple technique for histological studies of the rodent intestine. Lab. Anim. 15, 57-59 (1981).
30. Chen, X. & Calvisi, D. F. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am. J. Pathol. 184, 912-923 (2014).
31. Schira, J. et al. Significant clinical, neuropathological and behavioural recovery from acute spinal cord trauma by transplantation of a well-defined somatic stem cell from human umbilical cord blood. Brain 135, 431-446 (2012).
32. Cramer, T. et al. HIF-1a is essential for myeloid cell-mediated inflammation. Cell 112, 645-657 (2003).
33. Cotter, M. J., Norman, K. E., Hellewell, P. G. & Ridger, V. C. A novel method for isolation of neutrophils from murine blood using negative immunomagnetic separation. Am. J. Pathol. 159, 473-481 (2001).
34. Haslett, C., Guthrie, L. A., Kopaniak, M. M., Johnston, R. B. Jr & Henson, P. M. Modulation of multiple neutrophil functions by preparative methods or trace concentrations of bacterial lipopolysaccharide. Am. J. Pathol. 119, 101-110 (1985).
35. Shaked, Y. et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14, 263-273 (2008).